Clinical trial · Observational
Predictive Biomarkers for IGF1R Targeted Therapy in Ovarian Cancer: a Retrospective Study
NCT02719041CI-TRIAL-00021509unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The main goal of this study is to employ a novel proteomic approach to identify predictive tumor biomarkers that will increase the efficacy of insulin-like growth factor (IGF1R) targeted therapy in epithelial ovarian cancer. It is expected that these predictive biomarkers will be applied to increase the response rate in selected groups of patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Immunohistochemistry staining method | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Tissue samples
- description
- Tissue samples taken from women treated for ovarian cancer will be stained.
- interventionNames
- Other: Immunohistochemistry staining method
Primary outcomes (1)
- measure
- Responsive to IGF1R therapy
- timeFrame
- One year
- description
- Mean tumor volume will be calculated and growth inhibition will be reported as the percentage decrease of tumor volume compared with the control.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * women who underwent surgery for ovarian cancer Exclusion Criteria: * None
References
Publications (0)
Data not yet available
No reference posted for this study.